1 Malaria species positivity rates among symptomatic individuals across regions of 2 differing transmission intensities in Mainland Tanzania

- 3 Zachary R. Popkin Hall¹, Misago D. Seth², Rashid A. Madebe², Rule Budodo², Catherine
- 4 Bakari², Filbert Francis², Dativa Pereus², David J. Giesbrecht³, Celine I. Mandara², Daniel
- 5 Mbwambo⁴, Sijenunu Aaron⁴, Samwel Lazaro⁴, Jeffrey A. Bailey^{5,6}, Jonathan J. Juliano^{1,#}, Deus
- 6 S. Ishengoma^{2,7,8,#}
- ⁷ ¹Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill,
- 8 NC, USA 27599
- 9 ²National Institute for Medical Research, Dar es Salaam, Tanzania
- ¹⁰ ³The Connecticut Agricultural Experiment Station, New Haven, CT, USA 06511
- ¹¹ ⁴National Malaria Control Programme, Dodoma, Tanzania
- ¹² ⁵Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown
- 13 University, RI, USA 02906
- ⁶Center for Computational Molecular Biology, Brown University, RI, USA 02906
- ¹⁵ ⁷Harvard T. H. Chan School of Public Health, Boston, MA 02115
- ¹⁶ ⁸Faculty of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia
- 17 # co-senior authors

18 Abstract: Recent data indicate that non-Plasmodium falciparum species may be more

19 prevalent than previously realized in sub-Saharan Africa, the region where 95% of the world's

20 malaria cases occur. Although *Plasmodium malariae*, *Plasmodium ovale* spp., and *Plasmodium*

21 vivax are generally less severe than P. falciparum, treatment and control are more challenging,

- 22 and their geographic distributions are not well characterized. In order to characterize the
- 23 distribution of malaria species in Mainland Tanzania (which has a high burden and
- 24 geographically heterogeneous transmission levels), we randomly selected 3,284 samples from
- 12,845 samples to determine presence and parasitemia of different malaria species. The
- samples were collected from cross-sectional surveys in 100 health facilities across ten regions
- and analyzed via quantitative real-time PCR to characterize regional positivity rates for each
- species. *P. falciparum* was most prevalent, but *P. malariae* and *P. ovale* were found in all
- regions except Dar es Salaam, with high levels (>5%) of *P. ovale* in seven regions (70%). The highest positivity rate of *P. malariae* was 4.5% in Mara region and eight regions (80%) had
- 31 positivity rates $\geq 1\%$. We also detected three *P. vivax* infections in the very low-transmission
- 32 Kilimanjaro region. While most samples that tested positive for non-falciparum malaria were co-
- infected with *P. falciparum*, 23.6% (n = 13/55) of *P. malariae* and 14.7% (n = 24/163) of *P. ovale*
- 34 spp. samples were mono-infections. *P. falciparum* remains by far the largest threat, but our data
- indicate that malaria elimination efforts in Tanzania will require increased surveillance and
- 36 improved understanding of the biology of non-falciparum species.

Key Words: malaria, Tanzania, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax

39

40 Introduction:

41 Sub-Saharan Africa (SSA) accounted for 95% of malaria cases and 96% of malaria deaths in 2021[1]. Although Plasmodium falciparum is the most prevalent and deadliest human 42 43 malaria species in the SSA region, four other species are present (P. vivax, P. malariae, P. 44 ovale curtisi, and P. ovale wallikeri). Furthermore, recent research suggests that these four 45 species are more prevalent than previously thought and their prevalence may increase in the 46 context of intensive P. falciparum control/elimination[2-8]. This possibility is particularly salient 47 in light of current malaria elimination goals stemming from the WHO Global Technical 48 Strategy[9], which aims by 2030 to reduce the global malaria burden by 90% from 2015 levels. 49 Non-falciparum malaria species have notably different biology than *P. falciparum* and are not 50 necessarily controlled by the same measures, due to the potential for transmission by different 51 vectors, differing seasonality[10], potentially earlier gametocytogenesis[11-13], presence of hypnozoite stages/persistent infection[12,14], generally lower levels of parasite 52 53 carriage/density[15,16], and greater asymptomatic infection and transmission[10].

54 P. vivax is the most widely distributed human malaria species globally[17]. The strength 55 of Duffy selection with rapid sweep across SSA is testament to the morbidity and mortality that P. vivax has caused in the past[18]. Although generally less severe than P. falciparum[19], it 56 57 can be more difficult to control and treat due to the presence of the relapsing hypnozoite stage 58 in the liver[20]. Outside of Africa, e.g., in the Western Pacific, P. vivax has increased as P. 59 falciparum control has succeeded[1]. The prevailing dogma for decades was that P. vivax was 60 largely absent from Africa due to high prevalence of the Duffy-negative trait, which is widespread in most SSA populations[21]. However, recent evidence across Africa indicates 61 62 increased P. vivax detection in Duffy-negative patients[22-24]. Nonetheless, it is still much less 63 prevalent than P. falciparum and the clinical significance and management strategies of such 64 infections are still unknown.

P. malariae and P. ovale spp. are much less studied than either P. falciparum or P. 65 vivax. They have both been detected throughout Africa, but usually at much lower prevalence 66 than P. falciparum[25]. Both are frequently detected in co-infections with P. falciparum rather 67 than as mono-infections[15.25–28], although exceptions have been noted[29]. P. ovale spp. 68 69 infections are generally found at low-density, while P. malariae infections can cause higher 70 parasitemia[15]. P. ovale spp. have relapsing stages like P. vivax, which likely means that their 71 control and elimination will be more difficult, as is true of P. vivax[12]. P. malariae is thought to 72 be more prevalent than P. ovale, particularly in West Africa [5,6,14,15]. It does not have a liver 73 stage, but can cause long-term persistent infection[14].

74 While there are data to suggest that non-falciparum malaria is widespread in sub-75 Saharan Africa[4,26,28,30], and that these prevalences may be increasing[3,5,31], rapid diagnostic tests (RDTs) currently deployed in Africa are better at detecting falciparum malaria 76 77 than other species[32,33]. Given the preponderance of both low-density infections and multiple 78 species co-infections with non-falciparum malaria species, as well as the lower likelihood of 79 severe disease, these species are less likely to be detected during surveillance activities or at 80 the point-of-care. While molecular diagnostics such as gPCR are readily capable of detecting 81 both falciparum and non-falciparum *Plasmodium* spp., these tools are highly technical and resource-prohibitive, so are rarely used outside of laboratory research activities. 82

Tanzania has the third highest malaria burden in the world, accounting for 4.1% of global malaria deaths in 2021[1]. Malaria transmission in Tanzania is predominantly *P. falciparum* and highly heterogeneous by region and season (**Figure 1A**)[34]. Transmission is high and endemic along the coast and the Lake Zone, and low, unstable, and seasonal in large urban areas and highland regions, while the rest of the country is subject to moderate seasonal transmission[34].

88 Previous work has looked at prevalence of non-falciparum malaria among asymptomatic 89 school children, finding surprisingly high rates of P. ovale spp. infection[8]. However, data from 90 symptomatic cases for Tanzania is based primarily on sporadic convenience samples and does 91 not provide broad geographic information about the distribution of non-falciparum malaria. To address the distribution of non-falciparum malaria in symptomatic individuals from all age 92 93 groups, we conducted a survey of symptomatic malaria cases across ten different regions of 94 Mainland Tanzania with varying transmission intensity. We present a molecular analysis of malaria species positivity rates within this national dataset. 95



- 96
- Figure 1 A) National map of regional malaria prevalence in 2021 as determined by a combination of blood slide
 positivity rates and *Pfhrp2/LDH* mRDT positivity rates. Data courtesy of National Malaria Control Programme,
 Dodoma. B) Map of Tanzania highlighting study regions.
- 100

101 Methods:

102 *Ethics*:

103 The Molecular Surveillance of Malaria in Tanzania (MSMT) study protocol was approved by the

- 104Tanzanian Medical Research Coordinating Committee (MRCC) of the National Institute for
- 105 Medical Research (NIMR) and involved approved standard procedures for informed consent
- and sample deidentification. Additional details are described elsewhere[35]. Deidentified
- samples were considered non-human subjects' research at the University of North Carolina and
- Brown University. In addition, publicly available aggregate data on malaria prevalence from all
- regions of Tanzania was provided by the National Malaria Control Programme (NMCP) for 2021
- 110 in order to map regional malaria prevalence.
- 111 Sample collection:

112 A random subset of 3.284 samples were drawn from 12.845 samples collected during 113 the MSMT project[35] in 2021. Briefly, samples were collected in the MSMT Plasmodium falciparum histidine-rich protein 2 and 3 (Pfhrp2/3) gene deletion survey in ten regions: Dar es 114 115 Salaam, Dodoma, Kagera, Kilimanjaro, Manyara, Mara, Mtwara, Njombe, Songwe, and 116 Tabora[35], with additional samples collected in these regions for population genetic studies of malaria parasites. Additional details on study site selection are given in Rogier et al.[35]. 117 118 Surveys were conducted according to the WHO protocol[36] and included ten regions (Figure 119 **1B**) which are distributed across mainland Tanzania with variable malaria transmission levels. 120 Regions were assigned to four transmission strata ranging from very low to high based on 121 NMCP data from 2020[34] (Table 1).

122

Table 1 – Summary of study regions and number of samples analyzed

Region	Transmission Strata	Samples
Kilimanjaro	Very Low	897
Manyara	Very Low	223
Njombe	Very Low	211
Subtotal	Very Low	1,331
Dar es Salaam	Low	213
Dodoma	Low	274
Songwe	Low	145
Subtotal	Low	632
Mara	Moderate	335
Tabora	Moderate	267
Subtotal	Moderate	602
Kagera	High	417
Mtwara	High	302
Subtotal	High	719
Overall	All	3,284

123

Dried blood spots (DBS) were collected from patients with malaria-like symptoms. Most individuals (n = 3,234) were tested with a standard Pfhrp2/ pan-*Plasmodium* lactate dehydrogenase (pLDH) mRDT while some (n = 1,942) were also administered a PfLDH-based mRDT[35]. Samples were considered malaria-positive if any mRDT was positive.

128 Molecular speciation assays:

129 DNA from three 6mm DBS punches[37], representing approximately 25 µl of blood[8] 130 was extracted using Chelex into a final usable volume of approximately 100 µl. Quantitative real 131 time PCR assays targeting the 18S ribosomal subunit were performed according to published protocols (Supplemental Table 1)[28]. A separate qPCR assay was run for each species: P. 132 falciparum, P. malariae, P. ovale spp. (detecting both P. o. curtisi and P. o. wallikeri), and P. 133 134 vivax. Detection and parasitemia quantification were based on standard curves generated using 135 dilutions of plasmids from MR4 (MRA-177, MRA-178, MRA-179, MRA-180; BEI Resources, 136 Manassas, VA). Plasmids were quantified using a Qubit fluorometer, then normalized to a standard concentration of 0.1 ng/µL before serial dilutions. Three ten-fold dilution concentrations 137 138 (0.001 ng/µL, 0.0001 ng/µL, 0.00001 ng/µL) were used for qPCR standard curves. Semi-139 quantitative parasitemia was estimated based on the assumption of six 18S rRNA gene copies 140 per parasite genome[28], then multiplied by four to account for the dilution of eluted DNA 141 relative to initial blood volume[8]. P. malariae assays used 42 cycles, while all other assays

used 45 cycles to detect low-density infections[28]. This approach has been previously validatedas highly sensitive and specific[28,38].

144 Statistical analysis:

Positivity rates were calculated for each region, as the data are biased toward individuals with both clinical symptoms and mRDT positivity and therefore do not represent true prevalence inclusive of asymptomatic infections. Regional-level maps of positivity rate for each species were created using the R package *sf* (version 1.0-9) based on shape files available from GADM.org and naturalearthdata.com accessed via the R package *rnaturalearth* (version 0.3.2)[39].

Variation in species-specific positivity rates by region, transmission strata, individuals' age, and age group (young children <5 years, school-aged children 5-16 years[8,40], and adults >16 years) was assessed for significance with generalized linear models or ANOVA, as appropriate, in R. Given there is no consensus for an age range for school aged children, we used the age range of the 2017 Tanzania National School Children Survey[8,40].

156 **Results:**

157 Study Population:

158 Within this subset of 3.284 patients, the median age was 12 (IQR 3–28) years with a range 159 of 6 months to 87 years. Children (\leq 16 years old) constituted 56.4% of participants (n = 1,853), while adults (>16 years old) constituted the remaining 43.6% (n = 1,431). Young children (<5 160 161 years old) comprised 58.3% (n = 1.081) of the child participants, while the remaining 41.7% (n = 162 772) were school-aged (5 - 16 years old). Gender identifications were available for 3,196 participants and female-skewed, with 1,754 female (54.9%) and 1,442 male participants (45.1%). 163 164 Sample sizes for each region are given in **Table 1**. 53.7% (n = 1,763) of sampled individuals 165 tested positive by any mRDT.

166 *qPCR Positivity by Species:*

167Across all individuals sampled, *P. falciparum* was detected in 56.8% (n = 1,865, 95% CI:16855.1% - 58.5%), *P. malariae* in 1.7% (n = 55, 95% CI: 1.3% - 2.2%), *P. ovale* spp. in 5.0% (n =169163, 95% CI: 4.3% - 5.8%), and *P. vivax* in 0.09% (n = 3, 95% CI: 0.02% - 0.2%).

170 Mixed-species infections were common (**Table 2**). The majority of *P. malariae* infections 171 were mixed with P. falciparum (56.4%, n = 31), although P. malariae mono-infections were also 172 common (23.6%, n = 13), as were three-species infections with P. malariae, P. falciparum and P. ovale spp (18.2%, n = 10). The vast majority of P. ovale spp. infections were also mixed with P. 173 174 falciparum (78.5%, n = 128, Table 2). As with P. malariae, single-species infections occurred and 175 were more common than either three-species infections or mixed infection with P. ovale and P. 176 malariae only. Of the three P. vivax infections detected, all were mixed with P. falciparum (Table 177 **2**). This small sample size precluded further statistical analyses.

- 178
- 179

180

191

Table 2 - Infection composition proportions for non-falciparum infections

Infection Type	Count	Proportion
Pm	13	23.6%
Pm/Pf	31	56.4%
Pm/Po	1	1.8%
Pm/Pf/Po	10	18.2%
All Pm Infections	55	
Po	24	14.7%
Po/Pf	128	78.5%
Pm/Po	1	0.6%
Pm/Pf/Po	10	6.1%
All Po Infections	163	
Pv	0	0%
Pv/Pf	3	100%
All Pv Infections	3	

182

183 Parasite Density:

184 Parasitemia as determined by semi-quantitative qPCR based on standard dilutions of plasmid varied significantly (ANOVA p < 0.001) by species, with *P. falciparum* parasitemia the 185 186 highest at median (IQR) 1,226,000 p/µL (23,280 - 13,090,000 p/µL), followed by P. malariae at 187 389,920 p/µL (19,364 – 2,147,000 p/µL), and P. ovale spp. having the lowest median parasitemia at 3,970 p/µL (396 – 54,000 p/µL). A Tukey post hoc test detected a significant difference in 188 parasitemia (p < 0.001) between *P. falciparum* and *P. ovale* spp., but not between the other 189 190 species pairs. Parasitemia did not differ significantly between single and mixed-species infections 191 (Supplemental Figure 1). The three P. vivax infections (parasitemia of 70, 4,704, and 61,400 p/µL) 192 were not analyzed.

193 Variability by Region and Transmission Strata:

P. falciparum was detected in every region sampled (Figure 2A) with variable positivity
 rates (Table 3). *P. malariae* and *P. ovale* spp. were detected in every region except for Dar es
 Salaam (Figure 2B, 2C). *P. vivax* was only detected in Kilimanjaro region (Figure 2D).

^{*}Sum of proportions may not equal 100% due to rounding.



197

Figure 2 – Species positivity rate maps across Tanzania for A) *P. falciparum*, B) *P. malariae*, C) *P. ovale* spp., and D)
 P. vivax. Shaded regions represent only positivity rates among health facility samples and should not be assumed to represent true regional prevalences.

201

202

Table 3 - Positivity Rates by Region

<u>Region</u>	Pf Positive Samples	Pm Positive Samples	Po Positive Samples	Pv Positive Samples	<u>Total</u> Samples
Dar es Salaam	161 (75.6%)	0 (0%)	0 (0%)	0 (0%)	213
Dodoma	174 (63.5%)	5 (1.8%)	15 (5.5%)	0 (0%)	274
Kagera	261 (62.6%)	13 (3.1%)	24 (5.8%)	0 (0%)	417
Kilimanjaro	209 (23.3%)	2 (0.2%)	4 (0.4%)	3 (0.3%)	897
Manyara	144 (64.6%)	3 (1.4%)	14 (6.3%)	0 (0%)	227
Mara	240 (71.6%)	15 (4.5%)	51 (15.2%)	0 (0%)	335
Mtwara	238 (78.8%)	3 (1.0%)	10 (3.3%)	0 (0%)	302
Njombe	124 (58.8%)	6 (2.8%)	15 (7.1%)	0 (0%)	211
Songwe	93 (64.1%)	3 (2.1%)	14 (9.7%)	0 (0%)	145
Tabora	221 (82.8%)	5 (1.9%)	16 (6.0%)	0 (0%)	267

203 P. falciparum was most abundant in Tabora (82.8%, n = 221/267, Table 3) and Mtwara 204 (78.8%, n = 238/302), while it was least abundant in Kilimanjaro (23.3%, n = 209/897). P. malariae 205 was most abundant in Mara (4.5%, n = 15/335) and Kagera (3.1%, n = 13/417) and least abundant 206 in Kilimanjaro (0.2%, n = 2/897) and Mtwara (1.0%, n = 3/302). P. ovale spp. positivity rates surpassed 5% in seven regions, with the highest abundance in Mara (15.2%, n = 51/335), Songwe 207 (9.7%, n = 14/145), and Njombe (7.1%, n = 15/211). It was rare in Kilimanjaro (0.4%, n = 4/897). 208 209 In all ten regions, P. ovale positivity rates were higher than P. malariae. Positivity rates varied significantly by region for all three species (ANOVA p < 0.001). Overall, transmission strata had 210 211 a highly significant (ANOVA p < 0.001) effect on the positivity rates of all three species. Tukey 212 post hoc analysis between strata is shown in Figure 3.



213

Figure 3 – Tukey Analysis of Malaria Species Positivity Rate by Transmission Strata. A total of 1,331, 632, 602, and 719 samples were available in the very low, low, medium, and high transmission strata, respectively. The number of positive samples per strata for each species is shown in the X-axis labels. Level of significance is shown as follows: * p<0.05, ** p<0.01, *** p<0.001, or **** p<0.0001. Panel A shows *P. falciparum* parasite rates by strata. There were significant differences between most strata in pairwise comparison, therefore the only nonsignificant comparison is shown (NS). Panel B shows the *P. malariae* parasite rate by strata. Pairwise comparisons of strata with significant differences in parasite rate are shown (*). Panel C shows *P. ovale* spp. parasite rate by strata. Pairwise comparisons of strata with significant differences in parasite rate are shown (*).

222

Transmission strata had a significant effect on the likelihood of *P. falciparum* co-infection by ANOVA (p = 0.002) for *P. ovale* spp. A Tukey post hoc test indicated 24.6% (95% CI: 2.5% – 46.7%) fewer co-infections in very low vs. high transmission strata (p = 0.02) as well as 28.9% (95% CI: 0.97% – 48.1%) fewer co-infections in very low vs. moderate strata (p < 0.001). There was also a nearly significant (p = 0.06) reduction in co-infections between the very low and low transmission strata. By contrast, there was no significant effect on the likelihood of *P. malariae* co-infection with *P. falciparum*.

230 Variability by Age Group

No significant difference in *P. malariae* prevalence by age in years was detected (GLM p = 0.24). In contrast to *P. malariae*, age significantly correlated with *P. ovale* spp. infection (GLM p = 0.001). Children had significantly more *P. ovale* spp. infections (6.5%, n = 120/1,853) than

234 adults (3.0%, n = 43/1.431). When splitting participants into three age groups (**Figure 4**), overall 235 significant correlations by ANOVA were observed with qPCR positivity for P. falciparum (p < 236 0.001), P. malariae (p = 0.004), and P. ovale spp. (p < 0.001) (Figure 4). For P. falciparum, a Tukey post hoc test indicated significant variation (p < 0.001) between young children (<5 years), 237 school children (5 - 16 years), and adults (>16 years), with children more likely to be positive than 238 adults and school children more likely to be positive than young children. School children were 239 240 also more likely to be positive for *P. malariae* than either adults (p = 0.003) or young children (p = 0.03), but no significant differences were detected between young children and adults. For P. 241 242 ovale spp., school children were again more likely to test positive than either adults (p < 0.001) or 243 young children (p = 0.04), and young children were more likely to test positive than adults (p = 0.04) 244 0.01).



245 246 Figure 4 – Tukey Analysis of Malaria Species Positivity Rate by Age Strata. A total of 1,081, 772, and 1,413 247 individuals were in the Young Children (<5 years), School Children (5-16 years) and Adult (>16 years) strata, 248 respectively. The number of positive samples per age strata for each species is shown in the X-axis labels. Level of 249 significance is shown as follows: * p<0.05, ** p<0.01, *** p<0.001, or **** p<0.0001. Panel A shows P. falciparum 250 parasite rates by age strata. Pairwise comparisons of strata with significant differences in parasite rate are shown. All 250 251 252 other pairwise comparisons were nonsignificant. Panel B shows the P. malariae parasite rate by strata. Pairwise comparisons of strata with significant differences in parasite rate are shown. All other pairwise comparisons were 253 nonsignificant. Panel C shows P. ovale spp. parasite rate by strata. Pairwise comparisons of strata with significant 254 differences in parasite rate are shown. All other pairwise comparisons were nonsignificant.

256 **Discussion:**

255

257 This study presents a comprehensive picture of the geographic distribution of different malaria species among symptomatic patients within Mainland Tanzania across all ages and in 258 259 different transmission strata. It establishes a snapshot of the epidemiological landscape in 2021 260 that will enable effective longitudinal tracking of non-falciparum malaria. Plasmodium falciparum remains by far the most prevalent malaria species in Tanzania. Nonetheless, P. malariae and 261 262 especially P. ovale spp. are much more abundant than previously acknowledged, with multiple regions approaching or surpassing (in the case of P. ovale spp.) 5% positivity rates. P. vivax is 263 rarely detected and was found only in Kilimanjaro. 264

265 Our findings support a recent report of high rates of P. ovale infection among 266 asymptomatic school aged children in 2017[8]. Direct comparison between the studies is not possible due to the significant methodological differences (e.g. clinic-based symptomatic versus 267 268 school-based asymptomatic). However, we see predominately low density P. ovale infections 269 that are over-represented in the school aged individuals in this study. Though the 2017 study 270 identified *P. ovale* spp. primarily as mono-infections[8], we identified mostly mixed infections 271 with *P. falciparum* (Table 2). This discrepancy is most likely explained by our inclusion of 272 symptomatic patients in the study, as infection with P. falciparum likely led them to seek medical 273 care, while school children with P. ovale spp. mono-infections are more likely to be 274 asymptomatic[15]. Indeed, they constitute a major asymptomatic infectious reservoir[41–43].

The relatively high (> 5%) *P. ovale* spp. positivity rates in seven regions point to the 275 276 necessity of active surveillance for these species, particularly given data from Tanzania and elsewhere showing increased incidence[3,5,7,31]. As was seen by the 2017 study[8], we found 277 278 P. ovale spp. mono-infections to be more frequent in areas of low P. falciparum transmission, 279 even though our samples came from symptomatic patients reporting to health facilities. The 280 presence of these infections suggests that measures developed for P. falciparum will not 281 completely control malaria in these regions. Since P. ovale spp. develops hypnozoites which 282 can cause relapse, and which are not treated by standard schizonticidal regimens[12], its 283 control is more complicated than that of *P. falciparum*. While major aspects of its biology, including major vectors, are poorly understood, transmission may be seasonal and 284 285 asynchronous with P. falciparum[10]. Proactive monitoring will allow the NMCP and other 286 decision makers to regularly monitor incidence and implement P. ovale-specific control 287 measures as appropriate to support malaria control and elimination efforts.

288 While P. malariae was less abundant than P. ovale spp. in our study, it is nonetheless 289 present throughout Tanzania and also warrants regular surveillance. We identified few 290 significant differences in *P. malariae* positivity by transmission strata and no effect of 291 transmission strata on likelihood of co-infection with *P. falciparum*, but these results may stem 292 from small sample sizes (55 total P. malariae infections and 13 mono-infections). The relatively 293 low P. malariae levels detected in our study are also consistent with those found in other 294 surveys of Tanzania as well as Malawi and Western Kenya[8,28,44]. Taken together, these 295 results suggest that *P. malariae* is less of a concern than *P. ovale* spp. in East Africa. However, 296 transmission of *P. malariae*, like *P. ovale* spp., has been noted to increase as *P. falciparum* 297 transmission reduces throughout East Africa[2,3,5,16]. If these trends continue and both 298 species become more abundant, effective malaria control will increasingly hinge upon their 299 surveillance.

While there was significant regional variation in *P. malariae* and *P. ovale* spp. abundance in our study, it did not consistently correspond with transmission strata defined by *P. falciparum* data. In both *P. malariae* and *P. ovale* spp., the moderate transmission strata had the highest positivity rate, largely stemming from the high rates of both in Mara region. While *P. malariae* was equally likely to be co-infected with *P. falciparum* in all transmission strata, *P. ovale* spp. was more likely to occur as a single-species mono-infection in the very low transmission strata.

Based on our data, *P. vivax* remains a minimal concern in Tanzania. However, as with the other species, its incidence could increase as *P. falciparum*'s decreases and like *P. ovale* spp., it would require specialized treatment and control measures. Other studies have also

detected *P. vivax* at low levels in Kagera, Mara, and Mwanza[8,45], the coastal regions of

311 Mtwara and Tanga[8], and on the Zanzibar archipelago[16,46]. The fact that we did not detect

312 *P. vivax* in multiple regions is consistent with its characteristically low prevalence of $\leq 1\%$.

313 Because of its low prevalence, more intensive and targeted surveillance will be necessary to

understand the biology of *P. vivax* in Tanzania, but its clinical impact is likely minor compared to

315 the other species.

316 Case-based surveillance pilots targeting malaria elimination have been implemented within the very low transmission regions of Kilimanjaro and Manyara, with the goal of expanding 317 to other very low transmission regions [47]. While our results suggest that non-falciparum 318 319 species are present at low prevalence within Kilimanjaro, and therefore unlikely to present major 320 barriers to elimination in that region, Manyara has *P. ovale* spp. positivity rates > 5%, meaning 321 that elimination efforts within that region will need to account for the specific surveillance, 322 treatment, and control challenges presented by this species. Standardized treatment protocols 323 currently employed in Tanzania do not incorporate "radical cure" with primaquine or tafenoquine 324 to treat the liver-stage hypnozoites that cause relapses in *P. ovale* spp.[48]. As such, while ACT

325 treatment may clear blood-stage parasites, relapses will continue to occur.

326 This study has several limitations. Given the sampling scheme of using only people 327 presenting to the clinic with symptoms (whether they had mRDT-positive malaria or not) we are unable to determine true prevalence rates for each species and report parasite rate. This is due 328 329 to the fact that mRDT-positive individuals are likely over-enrolled and the asymptomatic 330 reservoir is not sampled. The addition of community surveys could help alleviate this. 331 Parasitemia estimates are also relative given the use of plasmids as the control and a multi-332 copy gene for detection. Better controls are needed for accurate quantification of non-falciparum 333 malaria using molecular methods. Lastly, while encompassing large regions of the country, the survey is not fully nationally representative and misses one crucial pre-elimination area, 334 335 Zanzibar, where data on non-falciparum malaria may be very beneficial for elimination plans.

336 Non-falciparum malaria, particularly P. ovale spp. and P. malariae, is present throughout mainland Tanzania. In order to achieve effective control and elimination of malaria, it will be 337 338 necessary to conduct further surveillance and research on these species. Ongoing research as 339 part of MSMT will enable both longitudinal epidemiological study and genomic characterization of the non-falciparum malaria landscape in Tanzania, as nationwide samples from 2022 and 340 341 2023 will be available, allowing a fuller picture of the abundance of *P. malariae*, *P. ovale* spp., and P. vivax within Tanzania, as well as an indication of temporal trends that are not detectable 342 343 in the work presented here. In addition, efforts to sequence high parasitemia P. malariae and P. 344 ovale spp. samples collected in 2021 are ongoing and will grant us a deeper and more comprehensive picture of the Tanzanian populations of these species. 345

Acknowledgements: The authors wish to thank participants and parents/guardians of all children 346 347 who took part in the surveillance. We acknowledge the contribution of the following project staff and other colleagues who participated in data collection and/or laboratory processing of samples: 348 349 Raymond Kitengeso, Ezekiel Malecela, Muhidin Kassim, Athanas Mhina, August Nyaki, Juma 350 Tupa, Anangisye Malabeja, Emmanuel Kessy, George Gesase, Tumaini Kamna, Grace Kanyankole, Oswald Osca, Richard Makono, Ildephonce Mathias, Godbless Msaki, Rashid 351 Mtumba, Gasper Lugela, Gineson Nkya, Daniel Chale, Richard Malisa, Sawaya Msangi, Ally 352 Idrisa, Francis Chambo, Kusa Mchaina, Neema Barua, Christian Msokame, Rogers Msangi, 353 354 Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusa, Jumaa Akida, Ambele

355 Yatinga, and Tilaus Gustay. We also acknowledge the finance, administrative and logistic support 356 team at NIMR: Christopher Masaka, Millen Meena, Beatrice Mwampeta, Gracia Sanga, Neema 357 Manumbu, Halfan Mwanga, Arison Ekoni, Twalipo Mponzi, Pendael Nasary, Denis Byakuzana, 358 Alfred Sezary, Emmanuel Mnzava, John Samwel, Daud Miema, Seth Nguhu, Thomas Semdoe, 359 Sadiki Yusuph, Alex Mwakibinga, Rodrick Ulomi and Andrea Kimboi. We are also grateful to the management of the National Institute for Medical Research, National Malaria Control Program 360 361 and President's Office-Regional Administration and Local Government (regional administrative secretaries of the 14 regions, and district officials, staff from all 100 HFs and Community Health 362 363 Workers from the 4 community cross sectional regions). Technical and logistics support from the 364 Bill and Melinda Gates Foundation team is highly appreciated. The following reagents were obtained through BEI Resources, NIAID, NIH: Diagnostic Plasmid Containing the Small Subunit 365 Ribosomal RNA Gene (18S) from Plasmodium falciparum, MRA-177; Plasmodium vivax, MRA-366 367 178; Plasmodium malariae, MRA-179; and Plasmodium ovale, MRA-180, contributed by Peter A. 368 Zimmerman.

369

370 Funding

This work was supported, in whole, by the Bill & Melinda Gates Foundation [grant number 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. JJJ also received funding from NIH K24AI134990.

375

376 **Data availability**: National malaria transmission data was provided by the National Malaria 377 Control Programme in Dodoma and is available by contacting NMCP. All other data is available

378 upon reasonable request to the corresponding author.

379 References:

- 380 1. World Health Organization. World malaria report 2022. Geneva; 2022.
- Akala HM, Watson OJ, Mitei KK, et al. Plasmodium interspecies interactions during a period of increasing prevalence of *Plasmodium ovale* in symptomatic individuals seeking treatment: an observational study. The Lancet Microbe [Internet]. **2021** [cited 2022 Mar 31]; 2(4):e141–e150. Available from:
- 385 https://linkinghub.elsevier.com/retrieve/pii/S2666524721000094
- Betson M, Clifford S, Stanton M, Kabatereine NB, Stothard JR. Emergence of Nonfalciparum *Plasmodium* Infection Despite Regular Artemisinin Combination Therapy in an 18-Month Longitudinal Study of Ugandan Children and Their Mothers. J Infect Dis [Internet]. Oxford Academic; **2018** [cited 2022 Mar 31]; 217(7):1099–1109. Available from: https://academic.oup.com/jid/article/217/7/1099/4791878
- Mitchell CL, Topazian HM, Brazeau NF, et al. Household Prevalence of *Plasmodium falciparum*, *Plasmodium vivax*, and *Plasmodium ovale* in the Democratic Republic of the Congo, 2013–2014. Clin Infect Dis [Internet]. Oxford University Press (OUP); **2020** [cited 2021 Mar 17]; Available from: https://academic.oup.com/cid/advancearticle/doi/10.1093/cid/ciaa1772/6006303
- Yman V, Wandell G, Mutemi DD, et al. Persistent transmission of *Plasmodium malariae* and *Plasmodium ovale* species in an area of declining *Plasmodium falciparum* transmission in eastern Tanzania. Marks F, editor. PLoS Negl Trop Dis [Internet]. Public Library of Science; **2019** [cited 2021 Apr 19]; 13(5):e0007414. Available from: https://dx.plos.org/10.1371/journal.pntd.0007414

401 6. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, et al. *Plasmodium malariae* contributes
402 to high levels of malaria transmission in a forest–savannah transition area in Cameroon.
403 Parasites Vectors 2023 161 [Internet]. BioMed Central; **2023** [cited 2023 Jan 30];
404 16(1):1–10. Available from:

- 405 https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05635-7
- 4067.Sendor R, Banek K, Kashamuka MM, et al. Epidemiology of *Plasmodium malariae* and407*Plasmodium ovale* spp. in a highly malaria-endemic country: a longitudinal cohort study in408Kinshasa Province, Democratic Republic of Congo. medRxiv [Internet]. Cold Spring409Harbor Laboratory Press; **2023** [cited 2023 May 2]; :2023.04.20.23288826. Available410from: https://www.medrxiv.org/content/10.1101/2023.04.20.23288826v1
- 8. Sendor R, Mitchell CL, Chacky F, et al. Similar Prevalence of *Plasmodium falciparum* and Non-*P. falciparum* Malaria Infections among Schoolchildren, Tanzania. Emerg Infect Dis [Internet]. 2023; 29(6):1143–1153. Available from: https://wwwnc.cdc.gov/eid/article/29/6/22-1016_article
- World Health Organization. Global Technical Strategy for Malaria 2016-2030 [Internet].
 Geneva; 2015. Available from: https://www.who.int/malaria/publications/atoz/9789241564991/ en/
- Tarimo BB, Nyasembe VO, Ngasala B, et al. Seasonality and transmissibility of *Plasmodium ovale* in Bagamoyo District, Tanzania. Parasit Vectors [Internet]. BioMed
 Central; **2022** [cited 2022 Feb 16]; 15(1):56. Available from:
 https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05181-2
- Herrichtzeiten Anderson Anders
- 426 12. Collins WE, Jeffery GM. *Plasmodium ovale*: Parasite and disease. Clin Microbiol Rev
 427 [Internet]. American Society for Microbiology; **2005** [cited 2022 Mar 31]; 18(3):570–581.
 428 Available from: https://journals.asm.org/doi/full/10.1128/CMR.18.3.570-581.2005
- Holzschuh A, Gruenberg M, Hofmann NE, et al. Co-infection of the four major *Plasmodium* species: Effects on densities and gametocyte carriage. PLoS Negl Trop Dis
 [Internet]. Public Library of Science; 2022 [cited 2023 Sep 12]; 16(9):e0010760. Available
 from: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010760
- 433 14. Oriero EC, Amenga-Etego L, Ishengoma DS, Amambua-Ngwa A. *Plasmodium malariae*,
 434 current knowledge and future research opportunities on a neglected malaria parasite
 435 species. Crit Rev Microbiol [Internet]. Taylor & Francis; 2021 [cited 2021 Jan 29]; 0(0):1–
 436 13. Available from:
- 437 https://www.tandfonline.com/doi/full/10.1080/1040841X.2020.1838440
- Roucher C, Rogier C, Sokhna C, Tall A, Trape JF. A 20-Year Longitudinal Study of *Plasmodium ovale* and *Plasmodium malariae* Prevalence and Morbidity in a West African
 Population. PLoS One [Internet]. Public Library of Science; **2014** [cited 2023 Mar 24];
 9(2):e87169. Available from:
- 442 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087169
- 44316.Cook J, Xu W, Msellem M, et al. Mass Screening and Treatment on the Basis of Results444of a *Plasmodium falciparum*-Specific Rapid Diagnostic Test Did Not Reduce Malaria

445 446 447		Incidence in Zanzibar. J Infect Dis [Internet]. Oxford Academic; 2015 [cited 2022 Mar 31]; 211(9):1476–1483. Available from: https://academic.oup.com/jid/article/211/9/1476/854482
448 449 450 451	17.	Battle KE, Baird JK. The global burden of <i>Plasmodium vivax</i> malaria is obscure and insidious. Seidlein L von, editor. PLOS Med [Internet]. Public Library of Science; 2021 [cited 2021 Oct 8]; 18(10):e1003799. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003799
452 453 454 455 456	18.	McManus KF, Taravella AM, Henn BM, Bustamante CD, Sikora M, Cornejo OE. Population genetic analysis of the DARC locus (Duffy) reveals adaptation from standing variation associated with malaria resistance in humans. PLOS Genet [Internet]. Public Library of Science; 2017 [cited 2023 Aug 7]; 13(3):e1006560. Available from: https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006560
457 458 459 460	19.	Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: A systematic review and meta-analysis of clinical studies since 1900. Malar J [Internet]. BioMed Central Ltd.; 2014 [cited 2023 Mar 24]; 13(1):1–10. Available from: https://link.springer.com/articles/10.1186/1475-2875-13-481
461 462 463 464	20.	Schäfer C, Zanghi G, Vaughan AM, Kappe SHI. <i>Plasmodium vivax</i> Latent Liver Stage Infection and Relapse: Biological Insights and New Experimental Tools. Annu Rev Microbiol [Internet]. Annual Reviews; 2021 [cited 2021 Jul 7]; 75(1):87–106. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev-micro-032421-061155
465 466 467	21.	Howes RE, Patil AP, Piel FB, et al. The global distribution of the Duffy blood group. Nat Commun [Internet]. 2011 ; 2(1):266. Available from: https://www.nature.com/articles/ncomms1265
468 469 470 471 472 473	22.	Leang R, Taylor WRJ, Bouth DM, et al. Evidence of <i>Plasmodium falciparum</i> Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. Antimicrob Agents Chemother [Internet]. American Society for Microbiology; 2015 [cited 2021 Jul 16]; 59(8):4719–4726. Available from: https://journals.asm.org/doi/10.1128/AAC.00835- 15
474 475 476 477	23.	Auburn S, Getachew S, Pearson RD, et al. Genomic Analysis of <i>Plasmodium vivax</i> in Southern Ethiopia Reveals Selective Pressures in Multiple Parasite Mechanisms. J Infect Dis [Internet]. Oxford University Press; 2019 [cited 2021 Jun 23]; 220(11):1738–1749. Available from: https://academic.oup.com/jid/article/220/11/1738/5298331
478 479 480 481	24.	Twohig KA, Pfeffer DA, Baird JK, et al. Growing evidence of <i>Plasmodium vivax</i> across malaria-endemic Africa. PLoS Negl Trop Dis [Internet]. Public Library of Science; 2019 [cited 2022 Aug 11]; 13(1):e0007140. Available from: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007140
482 483 484 485	25.	Sutherland CJ. Persistent Parasitism: The Adaptive Biology of Malariae and Ovale Malaria. Trends Parasitol [Internet]. Elsevier Current Trends; 2016 [cited 2023 Mar 24]; 32(10):808–819. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147149221630099X
486 487 488	26.	Mitchell CL, Brazeau NF, Keeler C, et al. Under the Radar: Epidemiology of <i>Plasmodium ovale</i> in the Democratic Republic of the Congo. J Infect Dis [Internet]. 2021 [cited 2020 Aug 11]; 223(6):1005–1014. Available from: https://academic.oup.com/jid/advance-

489 article/doi/10.1093/infdis/jiaa478/5885064

- 490 27. Mueller I, Zimmerman PA, Reeder JC. *Plasmodium malariae* and *Plasmodium ovale* –
 491 the 'bashful' malaria parasites. Trends Parasitol [Internet]. **2007**; 23(6):278–283.
 492 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471492207000906
- 493 28. Gumbo A, Topazian HM, Mwanza A, et al. Occurrence and Distribution of Nonfalciparum
 494 Malaria Parasite Species Among Adolescents and Adults in Malawi. J Infect Dis
 495 [Internet]. Oxford Academic; 2022 [cited 2023 Mar 27]; 225(2):257–268. Available from:
 496 https://academic.oup.com/jid/article/225/2/257/6318237
- 497 29. Sendor R, Mitchell CL, Chacky F, et al. Non-falciparum malaria infections are as
 498 prevalent as *P. falciparum* among Tanzanian schoolchildren. medRxiv [Internet]. Cold
 499 Spring Harbor Laboratory Press; **2022** [cited 2023 May 2]; :2022.06.07.22275625.
 500 Available from: https://www.medrxiv.org/content/10.1101/2022.06.07.22275625v1
- 50130.Mbama Ntabi JD, Lissom A, Djontu JC, et al. Prevalence of non-Plasmodium falciparum502species in southern districts of Brazzaville in The Republic of the Congo. Parasit Vectors503[Internet]. BioMed Central; **2022** [cited 2022 Jun 23]; 15(1):209. Available from:504https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05312-9
- 31. Hawadak J, Dongang Nana RR, Singh V. Global trend of *Plasmodium malariae* and *Plasmodium ovale* spp. malaria infections in the last two decades (2000–2020): a
 systematic review and meta-analysis. Parasites and Vectors [Internet]. BioMed Central
 Ltd; 2021 [cited 2023 May 2]; 14(1):1–14. Available from:
 https://link.springer.com/articles/10.1186/s13071-021-04797-0
- 510 32. World Health Organization. Malaria Rapid Diagnostic Test Performance. Geneva: World 511 Health Organization; 2009.
- 33. Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid
 Diagnostic Tests for the Detection of *Plasmodium knowlesi*, *Plasmodium malariae*, and *Plasmodium ovale* Monoinfections in Human Blood. J Infect Dis [Internet]. Oxford
 Academic; **2018** [cited 2023 Mar 24]; 218(2):265–276. Available from:
 https://academic.oup.com/jid/article/218/2/265/4938977
- 517 34. National Malaria Control Programme. Malaria Surveillance Bulletin 2022. Malar. Surveill.
 518 Bull. Dodoma; 2022.
- 51935.Rogier E, Battle N, Bakari C, et al. Plasmodium falciparum pfhrp2 and pfhrp3 gene520deletions among patients enrolled at 100 health facilities throughout Tanzania: February521to July 2021. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; **2023** [cited 2023522Aug 7]; :2023.07.29.23293322. Available from:
- 523 https://www.medrxiv.org/content/10.1101/2023.07.29.23293322v1
- 524 36. World Health Organization (WHO). Master protocol for surveillance of pfhrp2. 2020.
- 37. Plowe C V., Djimdé A, Bouaré M, Doumbo O, Wellems TE. Pyrimethamine and Proguanil
 Resistance-Conferring Mutations in *Plasmodium falciparum* Dihydrofolate Reductase:
 Polymerase Chain Reaction Methods for Surveillance in Africa. Am J Trop Med Hyg.
 1995; 52(6):565–568.
- 38. Brazeau NF, Mitchell CL, Morgan AP, et al. The epidemiology of *Plasmodium vivax*among adults in the Democratic Republic of the Congo. Nat Commun 2021 121 [Internet].
 Nature Publishing Group; **2021** [cited 2021 Jul 9]; 12(1):1–10. Available from:

- 532 https://www.nature.com/articles/s41467-021-24216-3
- Massicotte P, South A. rnaturalearth: World Map Data from Natural Earth [Internet]. 2023.
 Available from: https://cran.r-project.org/package=rnaturalearth
- Mitchell CL, Ngasala B, Janko MM, et al. Evaluating malaria prevalence and land cover
 across varying transmission intensity in Tanzania using a cross-sectional survey of
 school-aged children. Malar J [Internet]. BioMed Central; 2022 [cited 2022 Mar 11];
 21(1):80. Available from:
- 539 https://malariajournal.biomedcentral.com/articles/10.1186/s12936-022-04107-8
- Abdulraheem MA, Ernest M, Ugwuanyi I, et al. High prevalence of *Plasmodium malariae* and *Plasmodium ovale* in co-infections with *Plasmodium falciparum* in asymptomatic malaria parasite carriers in southwestern Nigeria. Int J Parasitol [Internet]. Pergamon;
 2022 [cited 2023 May 4]; 52(1):23–33. Available from:
- 544 https://linkinghub.elsevier.com/retrieve/pii/S0020751921002393
- Andolina C, Rek JC, Briggs J, et al. Sources of persistent malaria transmission in a
 setting with effective malaria control in eastern Uganda: a longitudinal, observational
 cohort study. Lancet Infect Dis [Internet]. Elsevier; **2021** [cited 2021 Jul 12]; 21(11):1568–
 1578. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309921000724
- 43. Walldorf JA, Cohee LM, Coalson JE, et al. School-Age Children Are a Reservoir of
 Malaria Infection in Malawi. PLoS One [Internet]. Public Library of Science; 2015 [cited
 2023 May 4]; 10(7):e0134061. Available from:
 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134061
- 44. Lo E, Nguyen K, Nguyen J, et al. *Plasmodium malariae* Prevalence and *csp* Gene
 Diversity, Kenya, 2014 and 2015 Volume 23, Number 4—April 2017 Emerging
 Infectious Diseases journal CDC. Emerg Infect Dis [Internet]. Centers for Disease
 Control and Prevention (CDC); **2017** [cited 2023 May 4]; 23(4):601–610. Available from:
 https://wwwnc.cdc.gov/eid/article/23/4/16-1245_article
- 45. Kim MJ, Jung BK, Chai JY, et al. High Malaria Prevalence among Schoolchildren on
 Kome Island, Tanzania. Korean J Parasitol [Internet]. The Korean Society for
 Parasitology and Tropical Medicine; **2015** [cited 2023 May 4]; 53(5):571–574. Available
 from: http://www.parahostdis.org/journal/view.php?doi=10.3347/kjp.2015.53.5.571
- 46. Msellem M, Kemere J, Mårtensson A, et al. Prevalence of PCR Detectable Malaria
 Infection among Febrile Patients with a Negative *Plasmodium falciparum* Specific Rapid
 Diagnostic Test in Zanzibar. Am J Trop Med Hyg [Internet]. **2013**; 88(2):289–291.
 Available from: https://ajtmh.org/doi/10.4269/ajtmh.2012.12-0095
- 47. U.S. President's Malaria Initiative. Tanzania (Mainland) Malaria Operational Plan FY
 2023. 2023.
- 48. Groger M, Veletzky L, Lalremruata A, et al. Prospective Clinical and Molecular Evaluation
 of Potential *Plasmodium ovale curtisi* and *wallikeri* Relapses in a High-transmission
 Setting. Clin Infect Dis [Internet]. Oxford Academic; **2019** [cited 2023 May 4];
- 571 69(12):2119–2126. Available from:
- 572 https://academic.oup.com/cid/article/69/12/2119/5486976
- 573
- 574

- 575 Supplemental Table 1 qPCR Reactions
- 576 (uploaded as separate Excel sheet)

577



Supplemental Figure 1 – Parasitemia for Mixed Infections with *P. falciparum* vs. Single-Species Mono-Infections for
 A) *P. malariae* and B) *P. ovale* spp. No significant difference was detected between mixed and mono-infections.